Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

VentriPoint Diagnostics Ltd V.VPT

Alternate Symbol(s):  VPTDF

Healthcare Medical Devices
Ventripoint Diagnostics Ltd. is a Canada-based medical device company. It is engaged in the development and commercialization of diagnostic tools to monitor patients with heart disease. It develops a suite of applications for all heart diseases and imaging modalities, including congenital heart disease, pregnancy, pulmonary hypertension, COVID-19, technically difficult imaging and cardiotoxicity in oncology patients. It provides application of artificial intelligence to echocardiography. Its flagship product, Ventripoint Medical System (VMS+), enhances echocardiography to deliver cMRI levels of accuracy for volumetric measurements and ejection fractions for all four chambers of the heart. It has developed a solution that transforms cardiac care through its 3D ECHO and MRI software. VMS products are powered by its proprietary Knowledge Based Reconstruction technology, which is the result of a decade of development and provides accurate volumetric cardiac measurements equivalent to MRI.


TSXV:VPT - Post by User

VentriPoint Diagnostics Ltd > Rocket67 on CEO.ca has Xmas solution
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(19)
•••
Comment by Enoughon Aug 31, 2022 9:59am
87 Views
Post# 34932095

RE:Rocket67 on CEO.ca has Xmas solution

RE:Rocket67 on CEO.ca has Xmas solution
Jennifer2020 wrote:
@Rocket67 RSNA 2022 starts November 27 and is the last chance this year for GEHC to make a "Big Splash". Yes there are other conferences but this is the biggest one and perfect for launching a huge digital platform like Edison. Not saying it's going to happen, they did buy BK Medical last Sept and featured at the RSNA last year.
 
0
 
@Rocket67 https://2022annual.com/rsna/
 
0



Maybe, hopefully, lets see....
This has been the stiry for over a year.
the launch has fizzled, and meanwhile Phillips is plugging along.

Then again that old video from 10 years ago I posted -said the same thing

This is getting repetitive and tiring

Launch already!
Get a sale...a single sale... 

<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities